Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition for treating osteoarthritis and application thereof

A technology of osteoarthritis and composition, applied in the field of pharmaceutical compositions for the treatment of osteoarthritis, can solve the problems such as unsatisfactory, insufficient effect and the like

Active Publication Date: 2019-08-02
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In addition, as a therapeutic agent for the above-mentioned joint degenerative diseases, a p21-activated kinase (PAK) antagonist (Japanese Patent Application Publication No. 2007-537134 ), which is a signal cascade system antagonist, or an antisense polynucleotide, nuclear Pharmaceutical compositions such as enzymes and small interfering RNAs (JP-A-2008-516593), but currently cannot obtain sufficient effects
[0006] In addition, in the current development of therapeutic drugs, the development of therapeutic drugs targeting cartilage regeneration promoting factors (interleukin (IL)-1, etc.) and the use of factors that induce cartilage repair and regeneration did not get satisfactory results

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for treating osteoarthritis and application thereof
  • Medicine composition for treating osteoarthritis and application thereof
  • Medicine composition for treating osteoarthritis and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation Embodiment 1

[0031] system Preparation Example 1 : pharmaceutical composition (powder) of the present invention

[0032] Captopril 1g;

[0033] Valsartan 4g;

[0034] Take the raw materials of the above active ingredients, sieve them, and mix them in a weight ratio of 1:4 to obtain the pharmaceutical composition (powder).

preparation Embodiment 2

[0035] Preparation Example 2 : pharmaceutical composition (solution) of the present invention

[0036] Get the pharmaceutical composition powder prepared in Example 1, and dissolve it in 50% ethanol aqueous solution (containing sodium lauryl sulfate) under ultrasonic to obtain the pharmaceutical composition (solution) of the present invention.

preparation Embodiment 3

[0037] Preparation Example 3 : pharmaceutical composition (tablet) of the present invention

[0038] Tablet prescription:

[0039]

[0040]

[0041] Preparation Process:

[0042] (1) Pretreatment of raw and auxiliary materials: crush and sieve the prescribed amount of captopril and valsartan (d(0.9) is 21.0 μm), pass lactose and microcrystalline cellulose through a 60-mesh sieve, and lauryl sulfate Sodium 60 mesh sieve pulverization;

[0043] (2) Add anhydrous lactose, microcrystalline cellulose, sodium lauryl sulfate, croscarmellose sodium, captopril and valsartan into the mixer, and mix for 20 minutes at 10 rpm;

[0044] (3) intermediate material obtained in step (2) is mixed with internally added magnesium stearate for 5min;

[0045] (4) Add the intermediate material obtained in step (3) to granulation in a dry granulator, and the sieve for granulation is 1.0mm;

[0046] (5) Add the intermediate material obtained in the step (4) into the mixer, and add the magne...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of combination of an angiotensin converting enzyme inhibitor and an angiotensin receptor antagonist in preparation of medicine for treating osteoarthritis, and further relates to a corresponding medicine composition.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a pharmaceutical composition for treating bone joints and its application. Background technique [0002] Osteoarthritis (OA) is the degeneration of the articular cartilage surface due to aging or mechanical stress, followed by the proliferation of new cartilage at the edge of the joint, joint deformation, and loss of fitness, and then develops into joint synovial inflammation disease. Osteoarthritis (OA) is a common disease characterized by progressive articular cartilage degeneration. The morbidity, teratogenicity and disability rate of OA are high, but its pathogenesis is still unclear and there is no effective treatment. [0003] Osteoarthritis-related disease typically manifests as cartilage loss and structural changes in the bursa, joint, and periarticular bone (Altman 1987; Altman et al., 1990). The damage of articular cartilage is one of the important problems of ost...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/41A61K31/401A61P19/02A61P19/08A61P29/00
CPCA61K31/401A61K31/41A61K45/06A61P19/02A61P19/08A61P29/00A61K2300/00
Inventor 曾羿沈彬蒋青杨静吴元刚斯海波包显超史冬泉胡钦胜马俊刘渊牟平
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products